ADME and Bioavailability of Selpercatinib in Healthy Men

Phase 1, open-label trial of selpercatinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC) and thyroid cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-time Curve, From Time 0 to the Time of the Last Quantifiable Concentration of Selpercatinib in Plasma (Part 1), Area Under the Concentration-time Curve, From Time 0 to the Time of the Last Quantifiable Concentration of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity and 9 more. Started Aug 2018; status: completed.